Human Stem Cells Institute OJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank, as well as the reproductive cell and tissue bank Reprobank (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant project to create its own Russia-wide network of Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD and NIPT among others).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Ask a question

About the Developer

Vitacel LLC is a biotechnological company specializing on development of innovative technologies based on the use of autologous (patient's own) cells and introducing these technologies into the medical practice. 

At present the company has two developed medical technologies which were approved by Roszdravnadzor: 

  1. to be used in esthetic medicine: the SPRS therapy (Service for Personal Regeneration of Skin) which is a complex of personified therapeutical and diagnostic procedures to restore the skin with signs of age-related changes and scars (FS authorization N 2009/308 of July 2010, At the end of 2009, the license on commercial realization of the SPRA therapy was transferred to the Human Stem Cells Institute (HSCI,, the leading Russian biotechnological company possessing the required experience and resources to commercially promote the cell technologies in the field of regenerative medicine.
  2. to be used in dentistry: the SPRS therapy (Service for Personal Regeneration of Skin) which is a complex of personified therapeutical procedures to restore the periodontal soft tissues (FS authorization N 2010/419 of December 9th, 2010) developed in cooperation with the Central Research Institute of Dental and Maxillofacial Surgery (Rosminzdrav,Russia). 

At present the company conducts research in the following directions: 

  • Development of the cell product to restore the periodontal bone tissue on the basis of patient's own cells (fibroblasts) isolated from gingival mucosa in order to use the complex approach to teeth treatment. The studies are conducted in cooperation with the Burnazyan Federal Medical Biophysical Center (the Federal Medical Biological Agency of Russian Federation), the Evdokimov Moscow State Medical Dentistry University, and the Baikov Institute of Metallurgy and Materials Science (theRussian Academyof Sciences, Moscow, Russia).
  • Development of the extended method to estimate the regenerative and proliferative potential of human skin fibroblast populations. The main goal is to provide the possibility to obtain the data on regenerative potential of patient's skin (the skin ability to restore) so that each physician-dermatologist (cosmetologist) could professionally design the individual program to restore the skin defects (age-related changes, scars, etc.). The studies are conducted in cooperation with the Moscow Research and Practical Center of Dermatovenerology and Cosmetology (the Moscow Health Department). 

All developments and technologies being currently under development are protected by a number of international and Russian patents (see section "Licenses").

Our Team